Journal
CANCERS
Volume 12, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/cancers12082106
Keywords
DYRK kinases; cellular signaling; expression dysregulation; cell cycle; cell survival; tumor progression; kinase inhibitors
Categories
Funding
- Spanish Ministry of Science and Innovation (AEI/FEDER) [BFU2016-76141-P]
- AGAUR grant from Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya [SGR14/674]
- CIBER de Enfermedades Raras
- La Marato of TV3
- Spanish Ministry of Science and Innovation
- Centro de Excelencia Severo Ochoa
- CERCA Programme/Generalitat de Catalunya
Ask authors/readers for more resources
DYRK (dual-specificity tyrosine-regulated kinases) are an evolutionary conserved family of protein kinases with members from yeast to humans. In humans, DYRKs are pleiotropic factors that phosphorylate a broad set of proteins involved in many different cellular processes. These include factors that have been associated with all the hallmarks of cancer, from genomic instability to increased proliferation and resistance, programmed cell death, or signaling pathways whose dysfunction is relevant to tumor onset and progression. In accordance with an involvement of DYRK kinases in the regulation of tumorigenic processes, an increasing number of research studies have been published in recent years showing either alterations of DYRK gene expression in tumor samples and/or providing evidence of DYRK-dependent mechanisms that contribute to tumor initiation and/or progression. In the present article, we will review the current understanding of the role of DYRK family members in cancer initiation and progression, providing an overview of the small molecules that act as DYRK inhibitors and discussing the clinical implications and therapeutic opportunities currently available.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available